Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Aide

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|July 12, 2003
Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary resultsThierry Jacob, Dany Grahek, Nassima Younsi, et al.
European Journal of Internal Medicine|September 4, 2017
Repetitive <sup>18</sup>F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled diseaseHubert de Boysson, Nicolas Aide, Eric Liozon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2010
High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearanceDelphine Denoyer, Ivan Greguric, Peter Roselt, et al.
Translational Oncology|October 24, 2013
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian CancerStéphanie Lheureux, Charlotte Lecerf, Mélanie Briand, et al.
Nuclear Medicine Communications|August 31, 2007
Improvement of semi-quantitative small-animal PET data with recovery coefficients: a phantom and rat studyNicolas Aide, Marie-Hélène Louis, Soizic Dutoit, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2006
Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?Françoise Montravers, Dany Grahek, Khaldoun Kerrou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2010
High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applicationsNicolas Aide, Cédric Desmonts, Jean-Mathieu Beauregard, et al.
Clinical Nuclear Medicine|August 18, 2012
Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancerCharline Lasnon, Rodney J Hicks, Jean-Mathieu Beauregard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 25, 2014
Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?Dimitri Bellevre, Cécile Blanc Fournier, Odile Switsers, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2010
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical studyNicolas Aide, Mélanie Briand, Pierre Bohn, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
European Journal of Nuclear Medicine and Molecular Imaging|July 12, 2003
Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary resultsThierry Jacob, Dany Grahek, Nassima Younsi, et al.
European Journal of Internal Medicine|September 4, 2017
Repetitive <sup>18</sup>F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled diseaseHubert de Boysson, Nicolas Aide, Eric Liozon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2010
High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearanceDelphine Denoyer, Ivan Greguric, Peter Roselt, et al.
Translational Oncology|October 24, 2013
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian CancerStéphanie Lheureux, Charlotte Lecerf, Mélanie Briand, et al.
Nuclear Medicine Communications|August 31, 2007
Improvement of semi-quantitative small-animal PET data with recovery coefficients: a phantom and rat studyNicolas Aide, Marie-Hélène Louis, Soizic Dutoit, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2006
Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?Françoise Montravers, Dany Grahek, Khaldoun Kerrou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2010
High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applicationsNicolas Aide, Cédric Desmonts, Jean-Mathieu Beauregard, et al.
Clinical Nuclear Medicine|August 18, 2012
Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancerCharline Lasnon, Rodney J Hicks, Jean-Mathieu Beauregard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 25, 2014
Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?Dimitri Bellevre, Cécile Blanc Fournier, Odile Switsers, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2010
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical studyNicolas Aide, Mélanie Briand, Pierre Bohn, et al.
Pageof 12